{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:58:03Z","timestamp":1792162683700,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.pharma.2009.05.004","type":"journal-article","created":{"date-parts":[[2009,7,19]],"date-time":"2009-07-19T04:09:45Z","timestamp":1247976585000},"page":"310-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Une nouvelle approche de la prise en charge de la schizophr\u00e9nie\u00a0: les agonistes partiels des r\u00e9cepteurs D2 de la dopamine"],"prefix":"10.1016","volume":"67","author":[{"given":"J.","family":"Costentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2009.05.004_bib1","first-page":"154","article-title":"Epid\u00e9miologie de la schizophr\u00e9nie","volume":"164","author":"Schmitt","year":"2006","journal-title":"Ann Med Psychol Rev Psychiatr"},{"issue":"1","key":"10.1016\/j.pharma.2009.05.004_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Per\u00e4l\u00e4","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharma.2009.05.004_bib3","first-page":"194","article-title":"Rauwolfia serpentina, a new indian drug for insanity and high blood pressure","volume":"2","author":"Sen","year":"1931","journal-title":"Indian Med World"},{"key":"10.1016\/j.pharma.2009.05.004_bib4","first-page":"206","article-title":"Un nouveau stabilisateur neurov\u00e9g\u00e9tatif\u00a0: le 4560 RP","volume":"60","author":"Laborit","year":"1952","journal-title":"Presse Med"},{"key":"10.1016\/j.pharma.2009.05.004_bib5","series-title":"Trente-huit cas de psychoses trait\u00e9es par la cure prolong\u00e9e et continue de 4560 RP C R Congr alien et neurol de langue fran\u00e7","author":"Delay","year":"1952"},{"key":"10.1016\/j.pharma.2009.05.004_bib6","series-title":"Dictionnaire des neuroleptiques","article-title":"Catalepsie","author":"Worms","year":"1989"},{"issue":"11","key":"10.1016\/j.pharma.2009.05.004_bib7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.2042-7158.1983.tb02880.x","article-title":"The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra","volume":"35","author":"Williams","year":"1983","journal-title":"J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharma.2009.05.004_bib8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1471-4159.1985.tb04092.x","article-title":"Serotonin agonists reduce dopamine synthesis in the striatum only when the flow of nigro-striatal neurons is intact","volume":"45","author":"Spampinato","year":"1985","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharma.2009.05.004_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.npp.1380239","article-title":"Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy","volume":"12","author":"Sumiyoshi","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pharma.2009.05.004_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0091-3057(85)90512-X","article-title":"The 5HT2 antagonist pirenperone reverses disruption of FR-40 by hallucinogenic drugs","volume":"22","author":"Mokler","year":"1985","journal-title":"Pharmacol Biochem Behav"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2009.05.004_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0014-2999(84)90030-X","article-title":"Some behavioral effects of hallucinogens are mediated by a postsynaptic serotonergic action: evidence from single unit studies in freely moving cats","volume":"101","author":"Heym","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1176\/appi.ajp.160.8.1413","article-title":"Is regionally selective D2\/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative (123I) epidepride SPET study of amisulpride-treated patients","volume":"160","author":"Bressan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharma.2009.05.004_bib13","unstructured":"Landry Y, Bertrand C. Approche fonctionnelle de la caract\u00e9risation des ligands et des r\u00e9cepteurs. In: Pharmacologie Mol\u00e9culaire 2e \u00e9d. 1993- Arnette. \u00c9ds Y. Landry, J-P. Gies. p.\u00a07\u201329."},{"key":"10.1016\/j.pharma.2009.05.004_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.bjp.0701196","article-title":"Evidence that antipsychotic drugs are inverse antagonists at D2 dopamine receptors","volume":"121","author":"Hall","year":"1997","journal-title":"Brit J Pharmacol"},{"issue":"Suppl.","key":"10.1016\/j.pharma.2009.05.004_bib15","first-page":"53","article-title":"Agonism and inverse agonism at dopamine D2 like receptors","volume":"1","author":"Strange","year":"1999","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharma.2009.05.004_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01244880","article-title":"Haloperidol increases prolactin release and cAMP formation in vitro, inverse agonism at D2 receptor","volume":"92","author":"Nilsson","year":"1993","journal-title":"J. Neural Transm"},{"key":"10.1016\/j.pharma.2009.05.004_bib17","unstructured":"Costentin J. Revue des principaux arguments \u00e9tayant l\u2019hypoth\u00e8se d\u2019une hyperactivit\u00e9 dopaminergique dans la schizophr\u00e9nie. In: Actualit\u00e9s de la schizophr\u00e9nie. Presse Universitaire de France. collect. Psychiatrie ouverte. \u00c9d. Pichot. 1981; Chap. 11; p. 169\u201393."},{"key":"10.1016\/j.pharma.2009.05.004_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis","volume":"109","author":"Tamminga","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharma.2009.05.004_bib19","first-page":"115","article-title":"A different balance in the sensitivity of D1 et D2 dopamine receptors accounts for differences in apomorphine-induced hypothermic effects in Swiss and C3H mice","volume":"31","author":"Suaudeau","year":"1992","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.2042-7158.1980.tb13018.x","article-title":"Evidence for thermoregulatory dopaminergic receptors located in the preopticus medialis nucleus of the rat hypothalamus","volume":"32","author":"Colboc","year":"1980","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3565(25)12799-7","article-title":"Effects of the novel antipsychotic agent 7-(4-[4- (2.3-dichlorophenyl) -1 piperazinyl] \u2013 butoxy) -3,4- dihydro-2 (1H) \u2013 quinolinone (OPC)-14597) on prolactine release from the rat anterior pituitary gland","volume":"277","author":"Inoue","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2009.05.004_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2007.07.031","article-title":"Differences in agonist\/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ\u00a0208-912","volume":"574","author":"Tadori","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/jm940608g","article-title":"Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7 [4-(4-phenyl-1-piperazinyl) butoxyl] -3,4-dihydro-2(1H) quinolinone derivatives","volume":"41","author":"Oshiro","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharma.2009.05.004_bib24","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/syn.20557","article-title":"Dopamine D2 high receptors moderately elevated by bifeprunox and aripiprazole","volume":"62","author":"Seeman","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.pharma.2009.05.004_bib25","first-page":"132","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorders","volume":"65","author":"Kane","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharma.2009.05.004_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","article-title":"Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic","volume":"515","author":"Tadori","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-2007-1017020","article-title":"The effect of OPC 4393 \u2013 a partial dopamine receptor agonist on negative symptoms: results of an open study","volume":"21","author":"Geraldo","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharma.2009.05.004_bib28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-3565(25)38169-3","article-title":"Electrophysiological effects of putative autoreceptor selective dopamine agonists on A10 dopamine neurons","volume":"265","author":"Ackerman","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl.","key":"10.1016\/j.pharma.2009.05.004_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0924-977X(95)00022-H","article-title":"Dopamine agonists in schizophrenia: a review","volume":"5","author":"Benkert","year":"1995","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF01244973","article-title":"An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics","volume":"84","author":"Olbrich","year":"1991","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.pharma.2009.05.004_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1055\/s-2007-1017021","article-title":"The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics","volume":"21","author":"Olbrich","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharma.2009.05.004_bib32","first-page":"S119","article-title":"Efficacy and safety of bifeprunox in the treatment of patients with acute exacerbation of schizophrenia: results of a dose-finding study","volume":"31","author":"Casey","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharma.2009.05.004_bib33","first-page":"S251","article-title":"Randomized, double blind, placebo-controlled study of bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia","volume":"31","author":"Barbato","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharma.2009.05.004_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0006-3223(97)00030-9","article-title":"Antipsychotic properties of the partial dopamine agonist (-) -3(3-hydroxyphenyl)-N-n-propyl piperidine (preclamol) in schizophrenia","volume":"43","author":"Lahti","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharma.2009.05.004_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2006.01.051","article-title":"Partial agonist properties of the antipsychotics SSR 181507, aripiprazole and bufeprunox at dopamine D2 receptors: G protein activation and prolactine release","volume":"535","author":"Cosi","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2006.08.063","article-title":"Aplindore (DAB 452) a high affinity selective dopamine D2 receptor partial agonist","volume":"552","author":"Heinrich","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/syn.20330","article-title":"In vitro characterization of SLV 308: a novel partial dopamine D2 and D3 receptor agonist and serotonin 5HT1A receptor agonist","volume":"60","author":"Glennon","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.pharma.2009.05.004_bib38","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/jpet.105.092155","article-title":"Intrinsinc efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethyl clozapine as D2\/D3 partial agonist","volume":"315","author":"Burnstein","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2009.05.004_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejphar.2006.11.016","article-title":"Dopamine partial agonist action of (\u2013) OSU 6162 is consistent with dopamine hyperactivity in psychosis","volume":"557","author":"Seeman","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharma.2009.05.004_bib40","first-page":"1211","article-title":"PD 158771, a potential antipsychotic agent with D2\/D3 partial agonist and 5HT1a agonist actions: II- Preclinical behavioural effects","volume":"39","author":"Corbin","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharma.2009.05.004_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","article-title":"Novel antipsychotic agents with 5HT(1a) agonist properties: role of 5HT(1a) receptor activation in attenuation of catalepsy induction in rats","volume":"49","author":"Kleven","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharma.2009.05.004_bib42","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs. cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5HT1A agonist property","volume":"31","author":"Kleven","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharma.2009.05.004_bib43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition cocaine-seeking behaviour by a partial dopamine D3 receptor agonist","volume":"400","author":"Pilla","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharma.2009.05.004_bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0269881105053308","article-title":"The place of partial agonism in psychiatry: recent developments","volume":"19","author":"Ohlsen","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharma.2009.05.004_bib45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorders","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:27:09Z","timestamp":1757719629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450909000820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0003450909000820"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2009.05.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Une nouvelle approche de la prise en charge de la schizophr\u00e9nie\u00a0: les agonistes partiels des r\u00e9cepteurs D2 de la dopamine","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2009.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}